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AbstrAct
Background This is an appraisal of the impact of 
cited research evidence underpinning the development 
of cancer clinical practice guidelines (CPGs) by the 
professional bodies of the European Society for Medical 
Oncology (ESMO), the National Institute for Health and 
Care Excellence (NICE) and the Scottish Intercollegiate 
Guidelines Network (SIGN).
Methods A total of 101 CPGs were identified from ESMO, 
NICE and SIGN websites across 13 cancer sites. Their 
9486 cited references were downloaded from the Web 
of Science Clarivate Group database, analysed on Excel 
(2016) using Visual Basic Application macros and imported 
onto SPSS (V.24.0) for statistical tests.
Results ESMO CPGs mostly cited research from Western 
Europe, while the NICE and SIGN ones from the UK, 
Canada, Australia and Scandinavian countries. The ESMO 
CPGs cited more recent and basic research (eg, drugs 
treatment), in comparison with NICE and SIGN CPGs 
where older and more clinical research (eg, surgery) 
papers were referenced. This chronological difference in 
the evidence base is also in line with that ESMO has a 
shorter gap between the publication of the research and 
its citation on the CPGs. It was demonstrated that ESMO 
CPGs report more chemotherapy research, while the NICE 
and SIGN CPGs report more surgery, with the results being 
statistically significant.
Conclusions We showed that ESMO, NICE and SIGN differ 
in their evidence base of CPGs. Healthcare professionals 
should be aware of this heterogeneity in effective decision-
making of tailored treatments to patients, irrespective of 
geographic location across Europe.
IntRoduCtIon
Clinical practice guidelines (CPGs) in 
oncology inform this expensive medical 
practice for the clinical care of patients 
with cancer. Use of CPGs has been shown 
to change clinical practice and improve the 
quality of patient care.1–3 
The European Society for Medical 
Oncology (ESMO) was founded in 1975 
and comprises a range of oncology stake-
holders from 130 countries.4 In the UK, 
the National Institute for Health and Care 
Excellence (NICE), set up in 1999, provides 
evidence-based recommendations on health-
care practice in England and Wales.5 The 
Scottish Intercollegiate Guidelines Network 
(SIGN) was set up in 1993 by the Academy 
of Royal Colleges for the National Health 
Service in Scotland6 with wider consultation 
from professional and patient representative 
groups.7
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Key questions
What is already known about this subject?
 ► Use of clinical practice guidelines (CPGs) has been 
shown to change clinical practice and improve the 
quality of patient care.
 ► Recommendations on CPGs should be based on the 
best available evidence; however, heterogeneity 
between development bodies has been 
demonstrated before.
 ► In this work, the research evidence base 
underpinning all the oncology CPGs published by 
European Society for Medical Oncology (ESMO), 
National Institute for Health and Care Excellence 
(NICE) and Scottish Intercollegiate Guidelines 
Network (SIGN) was assessed.
What does this study add?
 ► The differences are on national origins, time 
elapsed from publication to citation, research level 
(ie, basic or clinical) and research domain (eg, 
surgery, chemotherapy).
 ► The USA was the biggest contributor to the citations 
in the evidence base across all oncology CPGs.
 ► The ESMO CPGs cite mostly more basic 
research from Western Europe focusing on new 
chemotherapy agents or targeted treatments.
 ► The UK NICE and SIGN cite more clinical research 
from the UK, Canada, Australia and Scandinavian 
countries reporting more surgery.
How might this impact on clinical practice?
 ► This chronological difference in the evidence base 
is also in line with that ESMO has a shorter gap 
between the publication of the research and its 
citation on the CPGs.
 ► A closer collaboration between these professional 
bodies can lead to the use of more evidence-based, 
relevant and updated CPGs.
 ► Healthcare professionals using CPGs to personalise 
treatment regimens should be aware of these 
biases.
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Figure 1 Flow chart of the used methodology adapted from Moher et al.38 ESMO, European Society for Medical Oncology; 
NICE, National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network.
Recommendations on CPGs should be based on the 
best available evidence.8 9 An assessment of the research 
evidence base underpinning recommendations is 
important, as it demonstrates the degree of medical 
research transfer into practice.10–13 The mere assessment 
of the contribution of research papers by counting cita-
tions in the peer-reviewed literature10 does not reflect the 
impact of assimilation into clinical guidelines or imple-
mentation in care.11 14 15 The use of bibliometric analysis 
of CPGs addresses these gaps in understanding research 
activities, funding agenda and international collaboration 
in the cancer research arena, and guides public health 
policy.16–18
Pentheroudakis et al19 challenged the research and 
clinical community to rethink CPGs’ heterogeneity 
almost a decade ago. Are CPG developers using similar 
evidence bases? Or are these different interpreta-
tions of similar evidence bases? Here, we evaluate the 
evidence base of oncology CPGs and consider the clinical 
impact they could have on the CPGs developed by ESMO, 
NICE and SIGN.
MetHods
Oncology CPGs (n=101) were collected from the 
ESMO,20 NICE21 and SIGN22 websites and downloaded, 
with a cut-off date of 8 April 2017 (for the methodology, 
see figure 1). For their citation details, see online supple-
mentary appendix A – bibliography. Oncology CPGs were 
then classified using the ESMO system; this system has 13 
major cancer types based on anatomical region or organ 
system (see table 1).
Each CPG citation was then downloaded as a full record 
from the Web of Science (this is a tab delimited text file 
format). These text files were then processed using Visual 
Basic Application programs (Evaluametrics, St Albans, 
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Table 1 The list of the cancer sites is presented in alphabetical order, as classified according to topic and title of each of the 
identified cancer CPGs (based on the cancer anatomy classification)
No. Cancer sites (CPG topic) ESMO NICE and SIGN All
1 Breast cancer 4 (n=271) 4 (n=966) 8 (n=1237)
2 Cancers of unknown primary site 1 (n=25) 2 (n=217) 3 (n=242)
3 CNS malignancies 1 (n=68) N/A (n=0) 1 (n=68)
4 Endocrine and neuroendocrine cancers 4 (n=113) N/A (n=0) 4 (n=113)
5 Gastrointestinal cancers 11 (n=522) 5 (n=788) 14 (n=1310)
6 Genitourinary cancers 6 (n=385) 4 (n=1334) 10 (n=1719)
7 Gynaecological cancers 5 (n=185) 3 (n=486) 8 (n=671)
8 Haematological malignancies 14 (n=734) N/A (n=0) 14 (n=734)
9 Head and neck cancers 2 (n=24) 1 (n=464) 3 (n=488)
10 Lung cancer 10 (n=593) 2 (n=561) 12 (n=1154)
11 Sarcoma 3 (n=184) N/A (n=0) 3 (n=184)
12 Skin cancer 1 (n=37) 3 (n=450) 4 (n=487)
13 Sequelae or other cancers 13 (n=572) 2 (n=507) 15 (n=1079)
Total 13 oncology areas 75 (n=3713) 26 (n=5773) 101 (n=9486)
The table shows the allocation of the 101 ESMO, NICE and NICE CPGs for each cancer site and with the total number of references provided 
in brackets.
CNS, central nervous system; CPGs, clinical practice guidelines; ESMO, European Society for Medical Oncology; N/A, none available; NICE, 
National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network.
England). For an example, see online supplemen-
tary appendix B. The CPGs from NICE and SIGN were 
grouped and compared with those from ESMO.
Unless stated below, independent sample, unpaired 
Student’s t-tests have been used to compare groups of 
citations or CPGs. The SPSS Statistics V.24.0 software 
was used for statistical hypotheses testing regarding: (1) 
country contribution in the evidence base; (2) publi-
cation year of cited research papers; (3) chronolog-
ical research to reporting gap; (4) research level (RL) 
of papers; (5) cancer site applications; and (6) cancer 
research domains.
Addresses of contributing authors were available for 
9391 out of the 9486 research papers (99%). Multina-
tional citations were calculated on a fractional basis. The 
publication year of the citation was used to establish the 
interval between cited research and date of CPG. Pivot 
tables were used to count published papers by year and 
organisational body.
For journal titles, the RL of the cited papers was calcu-
lated based on keywords in the title, and of the journals in 
which they were published, using the system of Lewison 
and Paraje.23 Each cited paper is given a single value on 
a scale from 1.0=clinical to 4.0=basic science. The same 
process was repeated to get the average RL value for the 
journals in which these papers were cited. The mean 
RL for CPG citations was calculated by the following 
formula137:
 
RL = (N(clinical) + 4N(basic)2.5 ∗ N(both))/(N(clinical)
+N(basic)− N(both))  
The cancer sites application macro was used to allo-
cate one or more of the 13 tumour sites to each citation. 
Some papers did not specify a site and were grouped 
under ‘Sequelae or other cancers’ together with very low 
frequency cancer sites.
The burden of disease was measured in disability-ad-
justed life-years (DALYs) for 2012 provided by the WHO.24 
For each cancer site, this was taken as the percentage 
of total malignant neoplasm DALYs. Data on DALYs 
for sequelae, cancers of unknown origin, malignancies 
of the CNS, endocrine and neuroendocrine cancers, 
and sarcomas were grouped under ‘Sequalae or other 
cancers’, making the total of nine comparable groups by 
cancer site and disease burden.
The CPG citations were compared with the European 
oncology research papers, between 2002–2013. These 
were identified from the Web of Science using the Science 
Citation Index Expanded with a complex filter that 
contained 11 search statements; four listing 185 specialist 
journals in combination with seven listing 323 title words 
or phrases with no date restrictions.
Results
There were 9486 citations in 101 CPGs. Distribution by 
cancer sites and CPG development body is summarised 
in table 1.
Countries’ contributions in the evidence base
The USA was the biggest contributor to the citations 
in the evidence base across all oncology CPGs (see 
figure 2). Country ranks for the ESMO CPGs were 
then China and mostly Western Europe (Austria, Italy, 
Germany, France, Spain, Belgium, Switzerland and 
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Figure 2 For 24 countries with more than 20 citations, this figure compares contributions to ESMO and the UK cancer 
CPGs. Solid line of identity indicates equal proportionate contributions. The dotted lines represent a 2.5-fold deviation from 
identity: χ2=1.0, n=23 and P<0.05. Country ISO codes: AT, Austria; AU, Australia; BE, Belgium; BR, Brazil; CA, Canada; 
CH, Switzerland; CN, China; DE, Germany; DK, Denmark; ES, Spain; FI, Finland; FR, France; GR, Greece; IL, Israel; IT, Italy; 
JP, Japan; KR, South Korea; NL, The Netherlands; NO, Norway; PL, Poland; SE, Sweden; TW, Taiwan; UK, United Kingdom; 
US, United States. Countries in the upper left quadrant are skewed towards ESMO, while countries on the lower right quadrant 
are favoured by UK CPGs. CPG, clinical practice guideline; ESMO, European Society for Medical Oncology.
Poland). For the UK CPGs, the greatest country contribu-
tion following the USA, were the UK, Canada, Australia, 
Japan, Israel, South Korea, Taiwan, Italy, the Scandi-
navian countries (Denmark, Sweden and Finland) 
and Greece.
Inspection of the residual differences suggests that for 
NICE and SIGN, there is a positive skew towards litera-
ture from the UK and away from France, Spain, Belgium 
and Switzerland, as the most extreme examples of 
disproportionality.
Publication year of cited papers
The UK set of CPGs have a flatter distribution of citations 
than ESMO during the 22 year feasible period of observa-
tion (see figure 3).
Research to reporting gap
The greatest volume of cited references on ESMO 
CPGs (13.5%) have a very short reporting gap of 
only 1 year from when research was conducted to 
when cited in the guidelines, while those on the UK 
CPGs (10.5%) have a bigger gap of 4 years (results 
not shown). The cumulative percentages of the cited 
references with the gap in years are shown in figure 4. 
The mean gap of published research to reporting in a 
clinical guideline is 5.8 years for ESMO and 8.4 years 
for UK CPGs.
Rl of papers and journals of cited papers
The mean RL of the journals was very similar between 
the ESMO and UK NICE and SIGN, and had a trend 
towards the basic, not the clinical, end of the scale. The 
difference in the results was not statistically significant 
(P>0.05) in either CPG set.
In contrast to the journals, the majority of the 
oncology citations had an RL that was more clinical 
rather than basic, with a ratio of 10:1 for ESMO and 16:1 
for UK CPGs (table 2). The differences in the average 
RL papers’ values between ESMO and NICE and SIGN 
were statistically significant between the CPG groups. 
The UK CPGs cited slightly more clinical research 
papers compared with the ESMO ones.
Cancer sites application
The citations were sorted based on the cancer site 
according to the anatomical or organ-specific classifi-
cation (see Methods and figure 5). In total, there were 
nine malignant neoplasm sites (including ‘Sequelaer 
or other Cancers’) that could be compared with the 
disease burden measured in DALYs.
Overall, there was a better correlation between EU malig-
nant neoplasm DALYs and cancer research output for 
ESMO than the UK (except for haematological cancers). 
There are three observed patterns when comparing 
research citations with disease burden (DALYs). The item 
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Figure 3 The percentage (%) distribution of cited research papers by the year of their publication (solid boxes published 
between 2009 and 2015 for ESMO CPGs; open triangles, n=13 from NICE published in 2009–2015 and n=13 from SIGN 
published in 2005–2014). The cumulated difference between the 22 annual data points is statistically significant (P<0.05). CPG,  
clinical practice guideline; ESMO, European Society for Medical Oncology; NICE, National Institute for Health and Care 
Excellence; SIGN, Scottish Intercollegiate Guidelines Network.
Figure 4 The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK 
overall cancer clinical guidelines, with the difference between the two sets of data points being statistically significant 
(P<0.05). ESMO, European Society for Medical Oncology; NICE, National Institute for Health and Care Excellence; SIGN, 
Scottish Intercollegiate Guidelines Network. 
data are found  in online supplementary appendix C, table 
S1 for EU and table S2 for UK values.
The first pattern is seen for gastrointestinal carcinomas 
(GIS), lung cancer (LUN) and other cancer types (OTH). 
For these, it appears that the proportions of disease burden, 
as measured by WHO DALYs, are greater than the research 
papers cited on this CPG topic. This is true for both ESMO 
and the UK NICE and SIGN CPGs. For example, there 
is greater burden from GIS cancers in comparison with 
the research attention that is being cited, which include 
stomach, liver and colon cancer for the EU and UK regions, 
out of all carcinomas. This disproportionality was the same 
for both CPG groups.
The second pattern is characterised by breast (MAM), 
gynaecological (GYN), head and neck (HEN), 
genitourinary (GEN) and skin (including melanoma) 
(SKI) cancers. For these cancer sites, the proportion of 
cited research exceeds the proportion of DALYs-defined 
disease burden for the UK. This is not true for ESMO. 
On MAM, research citations are contributing about 11% 
to ESMO CPGs, while about 9% of the European popula-
tion is suffering from breast cancer, but this difference is 
not statistically significant (P>0.05). In contrast, for the UK, 
breast cancer research citations on CPGs are twice as much 
(18%) as the actual burden of disease in the UK (9%), with 
results being statistically significant (P<0.05).
A third pattern is observed only for haematological 
cancers, where there is a great research emphasis from 
ESMO clinical guidelines (24%), eightfold larger than the 
UK (~3%), despite a similar disease burden (7%) (P<0.01).
group.bmj.com on January 30, 2018 - Published by http://esmoopen.bmj.com/Downloaded from 
Open Access
6 Pallari E, et al. ESMO Open 2018;3:e000258. doi:10.1136/esmoopen-2017-000258
Table 2 The research level of the cited papers and the cited journals they are published in (85% of all citations had enough 
data for analysis)







ESMO 3043 321 214 3150 1.20* 1.31 1.55
UK NICE and SIGN 5259 324 244 4965 1.11* 1.27 1.41
*P<0.05 between CPG groups.
CPG, clinical practice guideline; ESMO, European Society for Medical Oncology; NICE, National Institute for Health and Care Excellence; RL, 
research level; SIGN, Scottish Intercollegiate Guidelines Network. 
Figure 5 The contribution of research papers by cancer application site on the two sets of cancer clinical practice guidelines, 
in comparison with the corresponding disease burden (EU and UK). The nine cancer application sites were gastrointestinal 
carcinomas (GIS), lung cancer (LUN), sequelae or other cancer types (OTH), breast cancer (MAM), haematological 
malignancies (HAE), genitourinary cancers (GEN), gynaecological cancers (GYN), head and neck cancers (HEN), sarcomas and 
skin cancer (SKI). On GIS: EU DALYs to ESMO papers’ difference and UK DALYs to NICE and SIGN papers: P>0.05; on MAM: 
EU DALYs to ESMO papers’ difference P>0.05 but UK DALYs and NICE and SIGN papers: P<0.05; on HAE: EU DALYs and 
ESMO, and UK DALYs to NICE and SIGN papers: P<0.01 in each case. For this purpose, two-tailed paired sample t-tests 
were used to compare citations on CPGs with the disease burden in the corresponding region (EU and UK). Blue dots: ESMO, 
Green dots: NICE & SIGN. DALYs, disability-adjusted life-years; ESMO, European Society for Medical Oncology; NICE, 
National Institute for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network.
Cancer research domains
Figure 6 shows the cited research for each of the 12 cancer 
research domains for the three sets of research papers: 
citations on EU ESMO CPGs, UK NICE and SIGN CPGs 
and European oncology research papers. The five main 
research domains were chemotherapy, targeted therapy, 
surgery, genetics and radiation therapy.
Chemotherapy was over-represented by a threefold in 
ESMO CPGs (29%) compared with the actual European 
output in oncology (11%) (P<0.01). The UK citations on 
CPGs are more proportionate (12%) as shown in figure 6.
For targeted therapies, a similar disproportion of the 
ESMO citations (12.3%) is observed, compared with 
1.1% in the UK CPGs and 3.2% in the European output 
(P<0.01). The UK CPGs cite 2.5 times more research on 
surgery (27%) than ESMO (12.2%) or the EU output 
(12.8%) (P<0.01).
For radiation therapy, a statistically significant dispro-
portion (P<0.05) is seen between the UK CPGs (14%), 
the European output (7%) and ESMO (10%). Finally, 
genetics research comprises a much higher proportion 
of the European oncology literature (19%) than the 
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Figure 6 The percentage (%) contribution of the cited research papers on all the oncology cancer research domains from 
the citations in ESMO, the UK cancer clinical guidelines and the European research outputs (n=282,055) in 2002–2013. Two-
tailed simple independent samples t-tests were performed to test for statistical significance between the research domains’ 
focus on the ESMO and UK separately. Also, two-tailed dependent samples t-tests were carried out for each group (ESMO 
and UK NICE and SIGN) to compare the percentage of cited research on CPGs with country research output assessment, 
only for the five main outstanding results. For CHEM: P<0.05; GENE: P<0.05; and SURG: P<0.01. The research domain codes 
are: CHEM, chemotherapy, DIAG, diagnosis, EPID, epidemiology, GENE, genetics, PATH, pathology, PALL, palliative care, 
PROG, prognosis, QUAL, quality of life research, RADI, radiotherapy, SCRE, screening, SURG, surgery and TARG, 
targeted therapy. CPGs, clinical practice guidelines; ESMO, European Society for Medical Oncology; NICE, National Institute 
for Health and Care Excellence; SIGN, Scottish Intercollegiate Guidelines Network.
research citations in either ESMO (8%) or UK CPGs 
(6%) (P<0.01).
dIsCussIon
Using proprietary macros, ESMO and the UK CPGs 
in oncology were compared on their underlying 
evidence bases. All oncology guidelines were influ-
enced by research from the USA. The ESMO CPGs also 
appear to be influenced mainly by research from Western 
Europe. The UK CPGs development is influenced by 
research conducted in the UK itself, Scandinavian coun-
tries, Canada, Australia, Japan, Israel, South Korea and 
Taiwan.
During a 22-year period, the UK CPGs on cancer indi-
cate a preference for older and more established clinical 
research in comparison with European guidelines that 
cite newer and experimental research. Out of the 12 
cancer research domains, it is evident that ESMO CPGs 
favour research on chemotherapy and targeted treat-
ments, while the UK NICE and SIGN ones emphasise 
surgery. The UK CPGs are slightly more clinical than the 
ones from ESMO, and focus on screening, radiotherapy 
or surgery, with the results being statistically significant.
There is a preference from ESMO on more recent 
research, which is especially evident from 2008 and a peak 
in 2012, prior to declining. In contrast, the UK NICE and 
SIGN development bodies present a delay in the uptake of 
more recent evidence in the guidelines with the research 
papers  having a wider gap from publication to citation. 
This mismatch of research interests corresponds to that 
between academia on theoretical frameworks, and clin-
ical practice.25 This temporal effect may also be because 
the ESMO cancer guidelines are more recent than the 
UK ones and cite newer research and hence, it is more 
likely that these research publications have greater inter-
national collaboration or even integrate more evidence-
based recommendations.
Strategies of guidelines’ maintenance have been 
debated.12 26 27 To find common ground between 
producing a timely and scientifically valid and rigorous 
clinical guideline, a pragmatic methodological compro-
mise is needed.28 29 A suggestion that the CPGs should be 
reassessed for validity every 3 years12 has been put forward 
and also challenged due to the use of a heterogeneous set 
of guidelines with variations in quality.30 This reporting 
preference can be perhaps justified that European 
cancer experts developing the ESMO CPGs cite research 
from Western Europe, as there are many Pan-European 
collaborations between the various institutions. An inter-
national collaboration is needed to exchange method-
ological information and avoid duplicated efforts.31 32
One limitation of this work is that the assessment of 
references for classification used for the CPGs was based 
on a standard anatomical categorisation of the various 
group.bmj.com on January 30, 2018 - Published by http://esmoopen.bmj.com/Downloaded from 
Open Access
8 Pallari E, et al. ESMO Open 2018;3:e000258. doi:10.1136/esmoopen-2017-000258
cancers as provided by the clinical guideline bodies. 
However, such grouping could hide recommendations 
based on genetic or gender differences in the popula-
tion. This is pertinent to the use of CPGs that provide 
no substitute to the complex clinical decision-making 
processes.19 33 34 The systematic collection, analysis and 
presentation of references forming the evidence base 
of the cancer clinical guidelines from ESMO, NICE and 
SIGN highlighted in this work, can provide the proto-
type for further research on the assessment of individual 
cancer sites such as breast cancer or haematology.
This study demonstrates that CPG heterogeneity begins 
with heterogeneity of the evidence bases. We agree with 
a previous study19 that suggested that diverse guidelines 
might be needed to meet divergent demands. A previous 
study demonstrated that the percentage of the cited 
papers in 15 CPGs (different topics including cancer) 
from UK bodies were 36% from US papers and 25% 
from the UK, followed by Canada 7% and Japan 2%.11 
This form of selective reporting bias is evident with other 
research that shows that the work of the UK, Denmark, 
Ireland and Sweden were overcited in UK oncology clin-
ical guidelines.15 This is the first time that a similar influ-
ence is shown for the ESMO clinical guidelines.
There is a potential solution for bias that threatens 
validity in clinical research, when fixed rules restrict 
comprehensive systematic review.35 It is known that papers 
cited on clinical guidelines are very clinical rather than 
basic.10 11 A systematic methodology for clinical guideline 
development is regarded as demanding, causing guide-
line developers to revert to consensus-based or expert-
based models instead.26 34 36 37
Divergent demands may well justify this differential 
research impact in clinical guideline development. This 
study showed that ESMO, NICE and SIGN differ in their 
evidence base, and healthcare professionals should be 
aware of this heterogeneity when using CPGs as part 
of effective decision-making of tailored treatments to 
patients, irrespective of geographic location across 
Europe.
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